

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended): A HeLa-S3 cell comprising a tumor or tissue-specific recombinant replication-competent adenovirus vector comprising a heterologous E2F-responsive transcriptional regulatory element (TRE), operatively linked to an Ela coding region.

Claim 2 (cancelled)

Claim 3 (withdrawn): The HeLa-S3 cell of Claim 1, wherein said tumor-specific replication-competent adenovirus vector comprises a mutation or deletion in the El b gene, wherein the encoded Elb protein lacks the capacity to bind p53.

Claim 4 (original): The HeLa-S3 cell of Claim 1, wherein said tumor-specific replication-competent adenovirus vector comprises a mutation or deletion in the Ela gene, wherein the encoded Ela protein lacks the capacity to bind RB.

Claim 5 (original): The HeLa-S3 cell of Claim 1, wherein said vector comprises a heterologous transcriptional regulatory element (TRE) sequence operatively linked to the coding region of a gene that is essential for replication of said vector, wherein said TRE functions in said cell so that replication of the vector occurs in said cell.

Claim 6 (original): The HeLa-S3 cell of Claim 5, wherein said TRE comprises a promoter or enhancer.

Claim 7-9 (cancelled)

Claim 10 (withdrawn): The HeLa-S3 cell of Claim 8, wherein said coding region is an E1b coding region

Claim 11 (withdrawn): The HeLa-S3 cell of Claim 8, wherein said coding region is an E2a coding region.

Claim 12 (withdrawn): The HeLa-S3 cell of Claim 8, wherein said coding region is an E2b coding region.

Claim 13 (withdrawn): The HeLa-S3 cell of Claim 8, wherein said coding region is an E4 coding region.

Claim 14 (Currently Amended): The HeLa-S3 cell of Claim 5, wherein said vector further comprises a second heterologous TRE operatively linked to the coding region of a second adenovirus gene that is essential for replication of said vector, wherein said second TRE functions in said cell so that replication of the vector occurs in said cell.

Claim 15 (original): The HeLa-S3 cell of Claim 14, wherein the first and second heterologous TRE sequences are different.

Claim 16 (original): The HeLa-S3 cell of Claim 5, wherein said vector further comprises a heterologous gene.

Claim 17 (original): The HeLa-S3 cell of Claim 16, wherein said heterologous gene encodes GM-CSF.

Claim 18 (original): A producer cell line comprising the cell of Claim 1.

Claim 19 (original): A producer cell line comprising the cell of Claim 5.

Claim 20 (original): A method of producing a replication-competent adenovirus, comprising culturing the HeLa-S3 cell of claim 1 and recovering said adenovirus from said cell or the supernatant of said cell.

Claim 21 (original): A method of producing a replication-competent adenovirus, comprising culturing the HeLa-S3 cell of Claim 5 and recovering said adenovirus from said cell or the supernatant of said cell.

Claim 22 (original): The method according to Claim 21, wherein said TRE comprises a promoter or enhancer.

Claim 23-24 (cancelled)

Claim 25 (Currently Amended): The method according to Claim 21, wherein said vector further comprises a heterologous gene.

Claim 26 (original): The method according to Claim 25, wherein said heterologous gene encodes GMCSF.